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Sepsis and septic shock are leading killers in the noncoronary
intensive care unit, and they remain worldwide health concerns.
The initial host defense against bacterial infections involves Toll-
like receptors (TLRs), which detect and respond to microbial li-
gands. In addition, a coordinated response of the adrenal and
immune systems is crucial for survival during severe inflammation.
Previously, we demonstrated a link between the innate immune
system and the endocrine stress response involving TLR-2. Like
TLR-2, TLR-4 is also expressed in human and mouse adrenals. In the
present work, by using a low dose of LPS to mimic systemic
inflammatory response syndrome, we have revealed marked cel-
lular alterations in adrenocortical tissue and an impaired adrenal
corticosterone response in TLR-4/ mice. Our findings demon-
strate that TLR-4 is a key mediator in the crosstalks between the
innate immune system and the endocrine stress response. Further-
more, TLR polymorphisms could contribute to the underlying
mechanisms of impaired adrenal stress response in patients with
bacterial sepsis.
lipopolysaccharide  stress axis  sepsis  corticoids  mice
Sepsis and septic shock, with a mortality of 20–80% (1), areleading killers in the noncoronary intensive care unit. In the
United States, the incidence of sepsis has risen from 164,072 cases
in 1979 to 659,935 in 2000, an increase of 13.7% per year (2). In the
1980s, Gram-negative bacteria were the predominant cause of
sepsis; however, by the year 2000,Gram-positive bacteria accounted
for 50% of all cases of sepsis in the United States. Despite the
increasing incidence of sepsis and sepsis-related conditions, the
overall mortality rate is declining, indicating the emergence of new,
improved strategies.
The initial host defense against bacterial infections is executed
essentially by pattern-recognition receptors, such as Toll-like re-
ceptors (TLRs), which detect and respond to microbial ligands. To
date, 10 TLRs have been identified in humans. TLR-4 has been
implicated in LPS signaling, innate immunity, and inflammation,
whereas TLR-2 is involved in the recognition of Gram-positive
bacteria (3–6). Clinical studies have demonstrated the existence of
TLR mutations in humans (7). TLR-2 and TLR-4 polymorphisms
are the most commonly identified, so far (8, 9). Moreover, TLRs
have been implicated in the dysregulation of innate immunity
during the pathological conditions of sepsis and cardiovascular
disease (10–12).
The endocrine system is essentially involved in an intact adrenal
response to stress, and it is crucial for the host defense against
infection (13, 14). This involvement is supported further by the fact
that adrenal insufficiency is associated with sepsis in a substantial
number of cases (15, 16). Hypothalamic hormones, including
corticotropin-releasing hormone and vasopressin, as well as inflam-
matory cytokines, such as IL-1, IL-6, and TNF-, have been
identified as important modulators of hypothalamic–pituitary–
adrenal (HPA) axis function (13, 14). During inflammation, these
cytokinesmediate a high glucocorticoid output, indicating a change
in regulation from the neuroendocrine to the immune–endocrine
system (17). As a result, high levels of adrenal glucocorticoids are
vital in preventing an uncontrolled inflammatory response to
cytokines, which could have detrimental effects on the cardiovas-
cular system. Therefore, during severe inflammation, a competent
response of the adrenal and immune systems is important for
survival (18–20).
Recently, we described the expression of TLR-2 in human and
mouse adrenals (21). TLR-2 plays an important role in the adrenal
stress response of mice because the absence of this receptor is
associated with an enlarged adrenal gland and reduced corticoste-
rone levels (22). Furthermore, plasma levels of adrenocorticotropic
hormone (ACTH) are elevated in TLR-2/ mice, indicating a
possible impairment of the HPA axis at the adrenal level. Like
TLR-2, TLR-4 is also expressed basally in human adrenals (21),
suggesting that both receptors may be involved in HPA axis
function. During the development of inflammatory conditions, a
role for TLR-4 in the endocrine stress response has not yet been
described. In the present work, we investigated the structure and
function of the adrenal gland in TLR-4-deficient mice during
experimental conditions of stress, e.g., systemic inflammatory re-
sponse syndrome. In the past, commercial LPS preparations con-
taminated with TLR-2 ligands were not considered (23, 24);
therefore, we also compared the effects of a pure LPS preparation
with a crude LPS preparation on the endocrine stress response.Our
results demonstrate that TLR-4 is amajormediator in the crosstalks
between the innate immune system and the endocrine stress
response.
Results
Structure and Function of the Adrenal Gland in TLR-4/Mice.Under
control conditions, TLR-4 proteinwas expressed in the adrenal cells
of WT mice (Fig. 1A). In TLR-4/ mice, the adrenal gland was
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significantly larger (272,000  14,000 pixels2) than in WT animals
(221,000  17,000 pixels2), as shown in Fig. 1 B and C (P  0.05).
This increase was caused by an enlarged adrenal cortex (Fig. 1D).
No differences were observed in the size of the adrenal medulla
between WT and TLR-4/ mice (Fig. 1E).
During control conditions, adrenal corticosterone production in
TLR4/ mice (466  26 ngml) was 4.5-fold higher (P  0.001)
than in WT mice (111  19 ngml; Fig. 2A). In contrast, plasma
ACTH levels were similar in the two animal groups (Fig. 2B;
P  0.05).
The differences in corticosterone production were accompanied
by marked morphological alterations in the adrenal cortex. In
Fig. 2. Adrenal function and structure. (A and B) Corticosterone (A) and
ACTH (B) levels in plasmawere obtained fromWTandTLR-4/mice (n 8per
group). Data analysis was performed by using Student’s t test; ***, P 0.001.
(C) An electron micrograph of adrenal cortical cells in the inner zona fascicu-
lata in WT mice is shown. The cytoplasm is filled with characteristic round
mitochondria with tubulovesicular cristae (MIT), ample smooth endoplasmic
reticulum, and liposomes (LIP). (D) An electron micrograph of adrenocortical
cells of TLR-4/ mice in the zona fasciculata is shown. Mitochondria of the
steroid-producing cells appear increased and more elongated with lamellar
andeven circular internalmembranesbridging themitochondrialmatrix.Nuc,
nucleus.
Fig. 3. Purity of LPS preparation. The purity of the LPS preparations was
determined by using an NF-B reporter gene assay in human embryonic
kidney 293 cells transfectedwith either TLR-2 or TLR-4. (A) Effects of a pure (p)
and a crude (c) LPS preparation (1–100 ngml) on NF-B-driven luciferase
activity in TLR-4-transfected cells (n  3). (B) Effects of pLPS and cLPS (1–100
ngml) on luciferase activity in TLR-2-transfected cells (n  3). Luciferase
activity was normalized to the -galactosidase control and is presented as
relative light units. Data analysis was performed by using a one-way ANOVA
followed by a Bonferroni posttest; *, P  0.05; **, P  0.01; ***, P  0.001.
Fig. 1. Adrenal size in TLR-4/ mice. (A)
TLR-4 expression in adrenal lysates from three
WT mice was analyzed by Western blotting.
(B) Histological adrenal specimens of WT and
TLR-4/mice are shown. (C–E) Determination
of adrenal surface (C), cortex surface (D), and
medulla surface (E) was performed in WT and
TLR-4/ mice (n  8 per group). Data were
analyzed with Student’s t test; *, P  0.05.







TLR-4/ mice, endothelial cells and macrophages were found
frequently in direct contact with adrenal cortical cells. In addition,
contact zones between the cortex and medulla were widened, and
particularly the zona reticularis appeared to be hypervascularized
(data not shown). At the ultrastructural level, the most pronounced
differences between WT and TLR-4/ animals were found in the
mitochondrial architecture (Fig. 2C andD). The steroid-producing
adrenocortical cells of WT animals revealed round mitochondria
with characteristic tubovesicular cristae and some electron-opaque
granules as described in ref. 25. In contrast, the mitochondria of
TLR-4/ adrenocortical cells showed a reorganization of the
cristae to lamellar or even circular structures, bridging the inner
matrix of the mitochondria (Fig. 2D). In addition, lipid-storing
droplets constituting the substrates for steroidogenesis were abun-
dant in adrenocortical cells of WT mice, but they were reduced
conspicuously in TLR-4/ mice.
Plasma Corticosterone and ACTH Response After LPS Challenges.
Having observed an increase in corticosterone production of
TLR-4/ mice, we then investigated corticosterone and ACTH
levels in response to LPS challenges. A comparison was carried out
by using a cLPS and pLPS preparation because in the past, several
observed effects of LPS have been attributed to contaminationwith
TLR-2 ligands. We investigated carefully the purity of our LPS
preparations by using a TLR-specific reporter gene assay. In
TLR-4-transfected human embryonic kidney 293 cells, the com-
mercial cLPS preparation as well as the pLPS caused a significant
increase in NF-B-driven luciferase activity (Fig. 3A). In contrast,
only cLPS but not pLPS induced TLR-dependent NF-B activity in
TLR-2-transfected cells (Fig. 3B). pLPS failed to increase luciferase
activity even at a concentration of 100 ngml, which reflects
approximately the in vivodosewehave used in this work. These data
therefore suggest that the pLPS preparation was free of TLR-2
ligands, whereas the cLPS preparation activated both TLR-2 and
TLR-4.
When cLPS and pLPS were injected into WT mice, both
preparations induced a 2- to 3-fold increase in the release of adrenal
corticosterone after 6 h compared with saline controls (P  0.05).
After 24 h, the stimulatory effect of LPS on adrenal corticosterone
production decreased (Fig. 4A). In contrast, no elevation in the
plasma levels of corticosterone was observed in TLR-4/ mice,
despite cLPS and pLPS challenges for 6 and 24 h (Fig. 4A).
Similarly, plasma levels of ACTH were increased (2.5-fold) after
cLPS but not pLPS treatment of WT mice (Fig. 4B). Like corti-
costerone, plasma levels of ACTH returned to baseline levels at
24 h. In TLR-4/ mice, neither pLPS nor cLPS had any effect on
the plasma levels of ACTH (Fig. 4B).
Profiles of Various Cytokines After cLPS and pLPS Challenges (6 and
24 h).Wenext determined the profile of various plasma cytokines
in untreated and LPS-challenged WT and TLR-4/ mice by
employing a sensitive multiplex immunoassay. Under normal
physiological conditions, control levels of the cytokines TNF-
and IL-12 were elevated significantly in TLR-4/ mice (Fig. 5
A and B). IL-1 was also increased, although plasma levels were
not of statistical significance (Fig. 5C).
WhenWTmice were challenged with cLPS, plasma levels of the
inflammatory cytokines were increased dramatically; however, this
effect was not observed with pLPS. After 6 h of treatment with
cLPS, IL-1 was increased approximately by 3-fold, IL-6 by 200-
fold, IL-12 by 80-fold, and TNF- by 10-fold compared with saline
treatment (Fig. 6 A–D, respectively). A similar trend was observed
with the antiinflammatory cytokine IL-10. cLPS (6 h) increased the
plasma levels of this cytokine (50-fold) significantly compared with
the saline group (Fig. 6E). After 24 h of cLPS treatment, the plasma
levels of all cytokines returned to levels that were similar to the
pLPS and saline groups. In TLR-4/mice, neither cLPS nor pLPS
had any effect on the plasma cytokines profiled. For IL-1, cLPS
appears to reduce its plasma level in TLR-4/ mice, although the
values were not statistically significant (Fig. 6A). All other cytokine
levels were comparable among groups for 6 and 24 h (Fig. 6 B–E).
Adrenal Activation of NF-B After cLPS and pLPS Challenges. NF-B
is an important regulator of proinflammatory cytokines; therefore,
we compared activation of this transcription factor in adrenal
extracts of WT and TLR-4/ mice. In adrenal cells of WT mice,
cLPS and pLPS treatment led to strong induction of NF-B DNA
binding activity, as evidenced by the appearance of a DNA–protein
complex (Fig. 7). This complex was specific for NF-B because
incubation of the cell extracts with either recombinant IB- or a
20-fold excess of the unlabeled oligonucleotide abolished DNA
Fig. 4. Plasma corticosterone and ACTH response after LPS challenges.
Plasma levels of corticosterone (A) and ACTH (B) were determined after 6 h or
24 h of i.p. treatment with 1 mgkg cLPS or pLPS in WT animals (n  8) and
TLR-4/mice (n7).Dataanalysiswasperformedbyusingaone-wayANOVA
followed by a Bonferroni posttest for each animal group; *, P  0.05.
Fig. 5. Basal levels of plasma cytokines in WT and TLR-4/mice. Plasma cytokines IL-12 (A), TNF- (B), and IL-1 (C) in untreated WT mice and TLR-4/mice (n
5–8 per group) were determined by a multiplex microsphere-based immunoassay. Data analysis was performed by using Student’s t test; *, P 0.05.
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binding (data not shown). In contrast, activation of NF-B was not
detected in TLR-4/ mice.
Discussion
The present work demonstrates a key role for TLR-4 in the adrenal
stress response. Under control physiological conditions the adrenal
gland is enlarged in TLR-4/ mice, and this phenomenon pre-
sumably represents a compensatory mechanism for maintaining
basal corticosterone release despite impaired adrenocortical func-
tion. It could also be argued that the altered structure of the
adrenals reflects the enhanced synthesis and release of corticoste-
rone in TLR-4/ mice. Furthermore, it is possible that increased
cytokine levels in TLR-4/ mice stimulate the adrenal cortex
directly to release corticoids. Intact steroidogenesis requires a
defined spatial and conformational arrangement of mitochondria
and their cristae, enabling optimal electron transfer and cyto-
chrome P450 activity. Therefore, the mitochondrial cristae of
steroid-producing cells are organized in a tubulovesicular pattern.
In TLR-4-deficient mice, however, adrenocortical cells exhibit
mitochondria with lamellar membranes or central dilatations. Fur-
thermore, adrenocortical cells of TLR-4/ mice show a marked
reduction of liposomes, which may result in a rapid exhaustion of
the adrenal lipid reserves on a massive stress stimulus such as
endotoxemia.
LPS elicits its effects specifically through the activation of TLR-4
(26). The majority of previous studies using commercial LPS
preparations did not take into consideration contamination with
TLR-2 ligands, such as lipopeptides (23, 24). This fact raises doubts
as to whether observations reported in earlier studies using LPS can
be attributed solely to the TLR-4 pathway, and instead the obser-
vations may reflect the activation of TLR-2. To exclude these
ambiguities, we compared the adrenal response in TLR-4/ by
employing two different LPS preparations. As confirmed by TLR-
specific reporter assays, the pLPS preparation solely triggered
Fig. 6. Profile of plasma cytokines after LPS challenges inWT and TLR-4/
mice. Plasma cytokines IL-1 (A), IL-6 (B), IL-12 (C), TNF- (D), and IL-10
(E) were determined in WT and TLR-4/ mice after an i.p. treatment
with 1 mgkg cLPS or pLPS or saline after 6 h or 24 h (n  5–8 per group).
Data analysis was performed by using a one-way ANOVA followed by
a Bonferroni posttest for each animal group; *, P  0.05; **, P  0.01; ***,
P  0.001.
Fig. 7. Adrenal NF-B activation in WT and TLR-4/ mice. (A) EMSA auto-
radiographsofNF-Bactivation in adrenal protein extracts fromWT (Left) and
TLR-4/ (Right) mice (n  5–8 per group) treated with 1 mlkg i.p. saline or
1mgkg i.p. cLPS or pLPS for 1 h. DNAbindingwas analyzedwith a 32P-labeled
NF-B-specific oligonucleotide. The NF-B–DNA complex is indicated by an
arrowhead; a nonspecific DNA complex is marked by a circle. (B) Quantifica-
tion of NF-B activation was assessed by PhosphorImager analysis. Data were
normalized to the intensity of thenonspecificDNAcomplex andare expressed
as -fold induction ofWT saline controls. Data analysis was performed by using
a one-way ANOVA followed by a Bonferroni posttest; *, P  0.05.







TLR-4, but was devoid of TLR-2 agonistic activity, whereas the
commercial cLPS preparation stimulated both receptors.
LPS stimulates various levels of the HPA axis, indicated by an
increase in plasma ACTH and corticosterone levels (27, 28).
Principally, it was thought that LPS exerts its main effects on
hypothalamic corticotropin-releasing hormone stimulation by cy-
tokine release. In turn, corticotropin-releasing hormone stimulates
ACTH release from the pituitary gland (29). However, other
studies have demonstrated endotoxin-stimulated effects on ACTH
and corticosterone levels by corticotropin-releasing hormone-
independent pathways (30, 31). Furthermore, corticosterone secre-
tion by endotoxin is also mediated by both pituitary (ACTH
stimulation) and extrapituitary mechanisms (e.g., histamine) (32,
33). There is also growing evidence to suggest that LPS elicits direct
effects on adrenal cells. Human adrenal cells release cortisol by
direct stimulation with LPS, an effect that is mediated by cycloox-
ygenase-dependent mechanisms (34, 35).
Under normal physiological conditions, 5 times higher basal
corticosterone levels were observed in TLR-4/ mice. The ele-
vated corticoids levels must mean that these adrenals were being
driven by some stimulus. ACTH was normal; therefore, increased
ACTH could have initiated elevations. Negative feedback of the
elevated levels of corticosterone returned the ACTH levels to near
normal. However, in TLR-2/ mice, which also have an enlarged
adrenal cortex, corticosterone levels are suppressed (22). On the
other hand, increased basal corticosterone levels in TLR-4/mice
may also be caused by increased basal levels of IL-12 and TNF-.
InWT animals, both preparations of LPS elicited a profound effect
on plasma corticosterone levels within the first 6 h; however, no
effect was observed in TLR-4-deficient mice. In these mice, an
inadequate response of corticosterone to pure LPS resulted from
the absence of TLR-4 signaling.After treatment with cLPS, the lack
of response to adrenal corticosterone could also have been caused
by the abolished activation of IL-1, TNF-, and IL-6. These
cytokines are released by peripheral immune cells in response to an
endotoxin challenge, and through the activation of the HPA axis,
they regulate corticosterone secretion (36, 37).
In contrast to corticosterone, the basal plasma levels of ACTH
remained unaltered in TLR-4/mice. Furthermore, unlike cLPS,
pLPS did not affect pituitary ACTH release in WT animals,
suggesting that a low dose of pLPS elicits its effects directly on the
adrenal gland through the activation of TLR-4. At the pituitary
level, cLPS-induced effects on ACTH release could have been
mediated by TLR-4 and TLR-2. The cLPS preparation used in this
study contained contaminants with TLR-2 agonists. This possibility
is in line with ref. 23, which demonstrated that commercial prep-
arations of LPS often contain low amounts of impurities that can
activate TLR-2 pathways. Two lipoproteins were found to be
responsible for TLR-2-mediated cell activation by Escherichia coli
LCD25 LPS (24).
Over the past few years it has become evident that the adrenal
gland is the main effector organ of the HPA axis and a major site
for both the synthesis and action of numerous cytokines (14). We
profiled the plasma release of several cytokines during basal and
LPS stimulation. Our study shows that both TNF- and IL-12 are
basally elevated in TLR-4/ mice, which may provide another
possible cause for elevated corticosterone levels, either by action in
the hypothalamic–pituitary unit or directly on the adrenal cortex.
However, increased output of these two cytokines did not alter the
basal release of ACTH from the pituitary, perhaps because of
negative feedback of the high basal corticoid levels in TLR-4/
mice. Furthermore, another interesting observation is a marked
reduction of IL-1 levels after 6 and 24 h after cLPS but not after
pLPS treatment (Fig. 6). The underlying mechanisms are currently
unknown, but a role for TLR-2 cannot be excluded.
Several studies have demonstrated the expression of the proin-
flammatory cytokines IL-1, IL-6, and TNF- in tissue of the HPA
axis (38, 39). Moreover, these cytokines regulate the hormonal
release and glucocorticoid output of the HPA axis (40). In rats,
IL-1, IL-6, TNF-, and IL-12 are expressed in the pituitary and
adrenal glands after cLPS stimulation (41). Therefore, it is not
surprising that after 6 h of cLPS stimulation, all plasma cytokines
were elevated in WT mice, indicating a competent inflammatory
response. In addition, IL-10, which, aside from its recognized role
in immunity also acts as an endogenous regulator of the HPA axis
(42), was increased after a cLPS stimulus in WT animals. In
contrast, pLPS had no effect in WT mice, indicating that TLR-2
signaling contributes to the observed activation of cytokines. This
finding is supported by our previous work, which demonstrated that
plasma levels of IL-1 and TNF- are attenuated in TLR-2/mice
but not abolished after cLPS treatment (22). In our work, the
increased plasma cytokines may also have contributed to the
elevated levels of ACTH.
Together with our previous work, this study reveals that during
experimental conditions of systemic inflammatory response syn-
drome, TLR-4 is an essential mediator of the adrenal stress
response. The absence of TLR-4 impairs the HPA axis primarily at
the adrenal level, providing further evidence that LPS mediates its
effects directly on adrenal cells; however, this impairment does not
appear to compromise the phenotype of TLR-4/ mice. Basal
alterations in adrenal structure and corticosterone and cytokine
activity suggest a functional role for TLR-4 in theHPA axis. Taking
these results together with our previous findings, TLR-2 and -4 are
shown to be key players in the immune and endocrine stress systems
during inflammation. Mutations in the innate immune system are
not rare events, and TLR polymorphisms may contribute to the
underlying mechanism for impairment of the adrenal stress re-
sponse in patients with sepsis.
Materials and Methods
Animals and Treatments. TLR-4/mice were generated by homol-
ogous recombination (43). WT (C57BL6) and TLR-4/ mice
were housed under standard conditions (55% relative humidity,
12-h day–night rhythm, standard chow, and water ad libitum). All
procedures were carried out in accordance with the Association for
Assessment and Accreditation of Laboratory Animal Care Inter-
national guidelines and Guide for the Care and Use of Laboratory
Animals (44) and were approved by German government ethical
and research boards. Animals (12–16 weeks old) were randomized
(n 8 per group) and treatedwith an i.p. injection for 6 or 24 hwith
1 mgkg saline, 1 mgkg cLPS (E. coli; serotype O111:B4; Sigma–
Aldrich), or a highly purified preparation of 1 mgkg pLPS (E. coli;
F515 LPS SB III,66). This dose of LPS was used to mimic the
conditions of systemic inflammatory response syndrome. After
each treatment, 0.5-ml blood samples were taken by aortic puncture
under sodium pentobarbital anesthesia, and the adrenal glands
were removed for analysis. Animals were killed by a terminal dose
of sodium pentobarbital. Saline 6- and 24-h groups demonstrated
similar values throughout the experiments; therefore, a saline
control represents both groups.
Purity of LPS Preparation. To determine the purity of our LPS
preparations we used a TLR-specific NF-B reporter gene assay
(45). Human embryonic kidney 293 cells stably expressing CD14
were cultured in DMEM supplemented with 10% heat-inactivated
FCS2 mM glutamine50 g/ml each penicillin and streptomycin.
Cells were plated in triplicate onto 12-well plates with 1 105 cells
per well. Transfection was performed by using FuGENE 6 reagent
(RocheDiagnostics) with anNF-B-controlled luciferase construct
(120 ng), Rous sarcoma virus -galactosidase (40 ng), and expres-
sion plasmids for either human TLR-2 or TLR-4 plus MD-2 (40 ng
each). Twenty-four hours after transfection, cells were stimulated
with a pLPS or cLPS preparation (0, 1, 10, or 100 ngml). After a
further 20-h incubation, the activities of luciferase and -galacto-
sidase (which was used as amarker for transfection efficiency) were
determined in cell extracts by using a chemiluminescence-based
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assay (RocheDiagnostics). Luciferase activities were calculated and
normalized to the -galactosidase control.
Western Blotting. Tissues were lysed in ice-cold protein extraction
buffer (150 mM NaCl50 mM TrisHCl, pH 7.41 mM EDTA5
g/ml leupeptin5g/ml aprotininA1mMPMSF0.1%SDS1%
sodium deoxycholate1% Triton X-100). After a brief centrifuga-
tion, the supernatant was removed. Total protein was determined
(Bradford assay), separated by SDSPAGE, and blotted onto
nitrocellulose membrane. The blots were probed with anti-TLR-4
antibody (11,000, L-14; Santa Cruz Biotechnology) and with
horseradish peroxidase-conjugated anti-goat secondary antibody
(13,000; Santa Cruz Biotechnology). After extensive washing,
protein bands were visualized by enhanced chemiluminescence
staining. Blots were also probed with anti--actin (Sigma–Aldrich;
13,000) to confirm equal loading of protein.
Morphometric Analysis. To determine the size of adrenal sections,
morphometric analysis was performed by using a computer-
supported imaging system connected to a light microscope (Eclipse
TE300, LUCIA G Software, Nikon, and Jerome Industry Phototype
P99135 camera, Digital Video Camera, Austin, TX). The area of
several sections wasmeasured in triplicate. The four largest sections
were evaluated for an approximation of the longest diameter in
each gland.
Electron Microscopy. Adrenal glands were fixed in 0.1 M phosphate
buffer at pH 7.3 with 2% (volvol) formaldehyde and glutaralde-
hyde. Tissue slices were postfixed for 90 min (2% OsO4 in 0.1 M
cacodylate buffer, pH 7.3), dehydrated in ethanol, and embedded
in epoxy resin. Ultrathin sections were stained with uranyl acetate
and lead citrate and examined at 80 kV in a CM 10 electron
microscope (Philips, Eindhoven, The Netherlands).
Plasma Corticosterone and ACTH.Plasma levels of corticosterone and
ACTH were determined quantitatively with an RIA (Diagnostic
Systems Laboratories, Webster, TX), as reported in ref. 22. The
inter- and intraassay coefficient of variation for corticosterone was
4.9% and 4.1%, and for ACTH, it was 4.0% and 5.9%, respectively.
Plasma Cytokines.Plasma levels of IL-1, -6, -10, and -12 andTNF-
(Mouse Cytokine multiPlex for Luminex laser; BioSource Europe,
Nivelles, Belgium) were determined by using themicrosphere array
technique (Luminex 100 system; Luminex, Austin, TX). Assays
were performed according to the manufacturer’s protocols with an
interassay coefficient of variation ranging from 5.2% to 10.4% for
all of the different cytokines.
EMSA.Adrenal extracts were prepared in a high-salt buffer [20 mM
Hepes, pH 7.9350 mM NaCl20% (vol/vol) glycerol1% Nonidet
P-401 mM MgCl20.5 mM EDTA0.1 mM EGTA0.5 mM
DTT1 mM PMSF2 g/ml aprotinin2 g/ml leupeptin]. The
extracts were cleared by centrifugation (17,500  g, 20 min, 4°C)
and assayed for protein by the Bradford method. Equal amounts of
protein (5g) were incubated at room temperature for 20 min with
the 32P-end-labeled NF-B-specific oligonucleotide (Promega) in a
20-l volume containing 4 l of extract, 4 l of 5 binding buffer
[50 mM Hepes, pH 7.550 mM KCl1 mM DTT2.5 mMMgCl2
50% (vol/vol) glycerol], 1 g of poly(dI-dC), and 2 g of BSA. The
samples were separated on nondenaturing 4% polyacrylamide gels
and quantified by PhosphorImager analysis.
Statistical Analysis. Data were analyzed by using Student’s t test or
one-way ANOVA in PRISM (GraphPad, San Diego). Results are
presented as the mean SEM. Statistical significance was defined
as follows: *, P  0.05; **, P  0.01; or ***, P  0.001.
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